Rabeprazole Sodium

+ 24 more variants

These side effects occur in a smaller percentage of the population but are still documented:

• Dizziness: A feeling of lightheadedness or vertigo.
• Rash: Minor skin irritations or itching.
• Constipation: Difficulty with bowel movements.
• Insomnia: Trouble falling or staying asleep.
• Dry Mouth: A decrease in saliva production.
• Myalgia: General muscle aches or pains without a clear cause.

Rare but documented side effects include:

• Gynaecomastia: Enlargement of breast tissue in males.
• Leukopenia or Thrombocytopenia: A decrease in white blood cells or platelets, which may increase infection or bleeding risk.
• Hepatitis: Inflammation of the liver, often marked by yellowing of the skin or eyes (jaundice).
• Interstitial Nephritis: A rare kidney inflammation that can lead to kidney failure.

> Warning: Stop taking Rabeprazole and call your doctor immediately if you experience any of these serious symptoms.

1. 1Severe Allergic Reactions (Anaphylaxis): Symptoms include hives, swelling of the face, lips, or throat, and difficulty breathing. This is a medical emergency.
2. 2Clostridioides difficile-Associated Diarrhea (CDAD): PPIs like rabeprazole may increase the risk of C. diff infection. Symptoms include watery stools, stomach pain, and fever that does not go away.
3. 3Hypomagnesemia (Low Magnesium): Long-term use (usually over one year) can cause magnesium levels to drop. Symptoms include tremors, seizures, muscle spasms (tetany), and irregular heartbeat (arrhythmias).
4. 4Systemic Lupus Erythematosus (SLE) or Subacute Cutaneous Lupus Erythematosus (SCLE): PPIs have been linked to the development or worsening of autoimmune lupus. Look for joint pain or a skin rash on the cheeks or arms that worsens in sunlight.
5. 5Acute Tubulointerstitial Nephritis: Signs include decreased urine output, blood in the urine, or sudden weight gain from fluid retention.

Extended use of rabeprazole (months to years) carries specific risks that patients and providers must monitor:

• Bone Fractures: Long-term, high-dose PPI therapy is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine. This is likely due to decreased calcium absorption.
• Vitamin B12 Deficiency: Gastric acid is required for the absorption of Vitamin B12 (cyanocobalamin) from food. Chronic acid suppression can lead to deficiency, resulting in anemia or nerve damage.
• Fundic Gland Polyps: Long-term use may lead to the development of small, benign growths in the upper part of the stomach. These are usually asymptomatic and found during endoscopy.
• Gastric Carcinoid Tumors: While primarily seen in animal studies with extreme doses, long-term hypergastrinemia (elevated gastrin levels) is a theoretical risk being monitored in humans.

No FDA black box warnings currently exist for Rabeprazole. However, the FDA has issued several safety communications regarding the risks of long-term PPI use, including the risk of fractures and C. diff infections, which are reflected in the standard warning sections of the drug's labeling.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular monitoring of magnesium and B12 levels may be recommended for those on long-term therapy.

Organ-Specific Risks

• Renal Effects: Acute tubulointerstitial nephritis has been observed in patients taking PPIs. This can occur at any point during therapy and is generally attributed to an idiopathic hypersensitivity reaction. If this occurs, the drug should be discontinued immediately.
• Hepatic Effects: While rabeprazole is primarily metabolized in the liver, significant hepatotoxicity is rare. However, in patients with severe hepatic impairment, the drug's half-life is doubled, necessitating careful monitoring.
• Bone Health: Increased risk of hip, wrist, or spine fractures has been noted, especially in patients receiving high doses or long-term (one year or longer) therapy. Patients should use the lowest dose and shortest duration of therapy appropriate to the condition being treated.

Vitamin and Mineral Malabsorption

• Hypomagnesemia: Low serum magnesium may occur after prolonged use. In some cases, this requires magnesium replacement and discontinuation of the PPI.
• Vitamin B12 Deficiency: Daily treatment with acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin.

For most short-term users, routine lab monitoring is not required. However, for those on long-term therapy or with underlying conditions, healthcare providers may monitor:

• Serum Magnesium: Prior to starting and periodically during long-term treatment.
• Vitamin B12 Levels: Especially in patients with low baseline stores or those on therapy for over 3 years.
• INR/Prothrombin Time: In patients also taking warfarin, as PPIs can occasionally interfere with warfarin metabolism.
• Bone Density: In patients at high risk for osteoporosis.

Rabeprazole is unlikely to impair the ability to drive or operate machinery. However, rare side effects such as dizziness or somnolence (drowsiness) have been reported. Patients should observe how they react to the medication before engaging in activities requiring mental alertness.

While there is no direct chemical interaction between rabeprazole and alcohol, alcohol consumption can increase gastric acid production and irritate the stomach lining. This may worsen the symptoms of GERD or peptic ulcers, effectively counteracting the benefits of the medication. It is generally advised to limit alcohol intake while treating acid-related disorders.

Abruptly stopping rabeprazole after long-term use can sometimes lead to "rebound acid hypersecretion." This occurs because the body has overcompensated for the drug's acid-blocking effects by producing more gastrin. When the drug is stopped, acid production may temporarily surge, causing symptoms to return more severely than before. If you have been on rabeprazole for a long time, your doctor may recommend tapering the dose.

> Important: Discuss all your medical conditions, including any history of liver disease or osteoporosis, with your healthcare provider before starting Rabeprazole.

• pH-Dependent Drugs: The absorption of certain drugs depends on the presence of gastric acid. By increasing the pH, rabeprazole may decrease the absorption of:
• Ketoconazole and Itraconazole (antifungals)
• Iron salts (supplements)
• Erlotinib and Gefitinib (cancer medications)
• Mycophenolate Mofetil (immunosuppressant)
• Clopidogrel: While the interaction is more pronounced with omeprazole, some studies suggest PPIs may slightly reduce the conversion of clopidogrel to its active metabolite via CYP2C19 inhibition. The clinical significance for rabeprazole is considered low, but caution is advised in high-risk cardiac patients.

• Timing with Food: While the AUC (total absorption) of rabeprazole is not significantly affected by food, taking the medication with a high-fat meal can delay absorption by 1.5 hours or more. For conditions like GERD, it is most effective when taken 30 minutes before a meal to ensure the drug is active when the proton pumps are most stimulated by eating.
• Dairy: There are no known significant interactions with dairy products.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4 and CYP2C19. It may significantly decrease the plasma levels of rabeprazole, rendering the treatment less effective.
• Ginkgo Biloba: May potentially interfere with the metabolism of drugs processed by the CYP system, though the clinical impact on rabeprazole is usually minimal.

• Chromogranin A (CgA) Levels: Increased CgA levels may occur secondary to PPI-induced hypergastrinemia. This can cause false-positive results in diagnostic tests for neuroendocrine tumors. PPIs should be temporarily stopped at least 14 days before CgA testing.
• Urine Screening for THC: Some PPIs have been reported to cause false-positive urine screening tests for tetrahydrocannabinol (THC). If a positive result occurs, a more specific confirmatory test should be performed.
• Secretin Stimulation Test: PPIs can cause a false-positive result in this test for gastrinoma. Treatment should be discontinued at least 3 days prior to the test.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs, to prevent dangerous interactions.

• Severe Hepatic Cirrhosis: Because the liver is the primary site of metabolism, severe impairment can lead to significantly elevated drug levels. While not an absolute contraindication, it requires extreme caution and lower dosing.
• Osteoporosis: Patients already at high risk for bone fractures should be evaluated carefully, as PPIs can further decrease calcium absorption and bone mineral density.
• Hypomagnesemia: Patients with existing low magnesium levels should have these corrected before starting rabeprazole, as the drug can worsen the condition.
• Pregnancy and Lactation: In the absence of definitive human data, use during pregnancy or breastfeeding is generally reserved for cases where the benefits clearly outweigh the potential risks to the fetus or infant.

There is a high degree of cross-sensitivity between rabeprazole and other proton pump inhibitors. If a patient has experienced an adverse immune-mediated reaction (like interstitial nephritis or a severe rash) with one PPI, they are likely to experience it with rabeprazole. However, patients who experience simple side effects like headache or nausea with one PPI may sometimes tolerate rabeprazole better due to its slightly different metabolic pathway.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies, before prescribing Rabeprazole.

Rabeprazole is approved for the treatment of GERD in children 1 year of age and older. It has not been studied or approved for children under the age of 1. In pediatric trials, the side effect profile was similar to that seen in adults, though there was a higher incidence of abdominal pain and upper respiratory tract infections. The long-term effects of acid suppression on growth and development in children are not fully known, so use should be limited to the shortest duration necessary.

In clinical trials, no overall differences in safety or effectiveness were observed between elderly subjects (65 years and older) and younger subjects. However, the elderly are more susceptible to certain complications of long-term PPI use:

• Fracture Risk: Increased risk of hip fractures due to age-related bone density loss.
• Nutritional Deficiencies: Higher likelihood of B12 or magnesium deficiency.
• Polypharmacy: Elderly patients are often on multiple medications (like diuretics or digoxin), increasing the risk of drug-drug interactions.

Pharmacokinetic studies in patients with stable end-stage renal failure receiving maintenance hemodialysis showed no clinically significant changes in the disposition of rabeprazole. No dosage adjustment is necessary for patients with any degree of renal impairment.

In patients with mild to moderate hepatic impairment, the AUC (area under the curve) of rabeprazole is approximately doubled compared to healthy volunteers. While dose adjustments are not strictly required for mild cases, patients with severe liver disease (Child-Pugh Class C) should be monitored very closely for adverse effects. There is limited data on the use of rabeprazole in patients with severe hepatic failure.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

|---|---|

| Bioavailability | ~52% (due to first-pass metabolism) |

| Protein Binding | 96.3% (primarily to albumin) |

| Half-life | 1 - 2 hours (plasma); effect lasts 24-48 hours |

| Tmax | 2.0 - 5.0 hours (delayed by food) |

| Metabolism | Primarily non-enzymatic; also CYP2C19 and CYP3A4 |

| Excretion | Renal 90%, Fecal 10% |

• Molecular Formula: C18H20N3NaO3S
• Molecular Weight: 381.43 g/mol (as sodium salt)
• Solubility: Very soluble in water and methanol; freely soluble in ethanol.
• Structure: Rabeprazole is a substituted benzimidazole. It consists of a benzimidazole ring linked to a pyridine ring by a methylsulfinyl group. This structure allows it to function as a prodrug that is activated only in highly acidic environments.

Rabeprazole is classified as a Proton Pump Inhibitor (PPI). It is part of a therapeutic class that includes omeprazole, lansoprazole, pantoprazole, and esomeprazole. Within this class, rabeprazole is noted for its rapid onset of action and its metabolism pathway, which is less dependent on the CYP2C19 enzyme than some of its counterparts.